Primary histiocytic sarcoma: a clinicopathologic study of two cases

Yu GUAN,Chun WU,Xuan WANG,Shan-shan SHI,Sheng-bing YE,Heng-hui MA,Qun-li SHI,Xiao-jun ZHOU,Qiu RAO,Yang TAN

DOI: https://doi.org/10.3969/j.issn.1007-8096.2018.05.010

2018-01-01

Abstract:Objective To discuss the clinical pathological features,diagnosis,differential diagnosis,treatment and prognosis of primary histocytic sarcoma (HS).Methods The clinical pathological characteristics of 2 cases of primary HS (2012-2016) were observed,and related literature was reviewed.Results Case 1 38-year-old male presented with recurrent fever for 3 months.Multiple lymph nodes enlargement was found in the bilateral anterior and supraclavicular regions.After the admission the lymph node biopsy was performed.Case 2,female,21 years old,presented the right upper extremity pain with pathological fracture for 1 month.The performence of right proximal humerus tumor curettage and bone grafting and internal fixation was conducted after the admission.Microscopically,a large number of mononuclear like tissue cells were diffusely distributed.The tumor cells were large in size,eosinophilic or vacuolated in cytoplasm,and the nuclei showed round,oval and irregular.The pathological mitotic figures were common.Immunohistochemically,the tumor cells showed positive for CD68,CD163 and lysozyme,and negative for SMA,Desmin,CD3,S-100,CD30,CD20,CD43,EMA,HMB45,CD21/35,Clusterin,Langerin and CD1a.There was a BRAF V600E mutation in case 2.Conclusion Histiocytic sarcoma is a highly malignant tumor with a lack of specificity in clinical manifestations.The diagnosis is made by pathological morphology and immunohistochemistry.The tumor should be differentiated from other malignancies of the hematopoietic system.For patients with BRAF V600E mutation,the use of vemurafenib targeted therapy may achieve some efficacy,but still needs a large-scale clinical verification.